A subpopulation of malignant CD34+CD138+B7-H1+ plasma cells is present in multiple myeloma patients

Experimental Hematology

Volumn 38, Issue 2, 2010, Pages

  Kuranda, Klaudia ^a,b   Berthon, Céline ^a,b,c   Dupont, Caroline ^a,b   Wolowiec, Dariusz ^d   Leleu, Xavier ^a,b,c   Polakowska, Renata ^a,b   Jouy, Nathalie ^b   Quesnel, Bruno ^a,b,c  

^a Institut de Recherche sur le Cancer de Lille   (France)

^b UNIV LILLE   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; CD34 ANTIGEN; KI 67 ANTIGEN; LYMPHOCYTE ANTIGEN; PROGRAMMED DEATH 1 LIGAND 1; SYNDECAN 1;

ADULT; AGED; ANIMAL CELL; ANTIGEN EXPRESSION; ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CELL GROWTH; CELL ISOLATION; CELL POPULATION; CELL PROLIFERATION; CELL SELECTION; CELL STRUCTURE; CELL SUBPOPULATION; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LYMPHOMA CELL LINE; MALE; MOUSE; MULTIPLE MYELOMA; NONHUMAN; NONOBESE DIABETIC MOUSE; PLASMA CELL; PRIORITY JOURNAL; SCID MOUSE;

MUS;

EID: 73949099918     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2009.11.008     Document Type: Article

References (25)

1. Huff C.A., and Matsui W. Multiple myeloma cancer stem cells. J Clin Oncol 26 (2008) 2895-2900
2. Matsui W., Wang Q., Barber J.P., et al. Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res 68 (2008) 190-197
3. Bataille R., Robillard N., Pellat-Deceunynck C., and Amiot M. A cellular model for myeloma cell growth and maturation based on an intraclonal CD45 hierarchy. Immunol Rev 194 (2003) 105-111
4. Keir M.E., Butte M.J., Freeman G.J., and Sharpe A.H. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 26 (2008) 677-704
5. Vescio R.A., Hong C.H., Cao J., et al. The hematopoietic stem cell antigen, CD34, is not expressed on the malignant cells in multiple myeloma. Blood 84 (1994) 3283-3290
6. Johnson R.J., Owen R.G., Smith G.M., et al. Peripheral blood stem cell transplantation in myeloma using CD34 selected cells. Bone Marrow Transplant 17 (1996) 723-727
7. Schiller G., Vescio R., Freytes C., et al. Transplantation of CD34+ peripheral blood progenitor cells after high-dose chemotherapy for patients with advanced multiple myeloma. Blood 86 (1995) 390-397
8. Owen R.G., Haynes A.P., Evans P.A., et al. Detection of clonal immunoglobulin gene rearrangements in the peripheral blood progenitor cells of patients with multiple myeloma: the potential role of purging with CD34 positive selection. Clin Mol Pathol 49 (1996) M112-M117
9. Willems P., Croockewit A., Raymakers R., et al. CD34 selections from myeloma peripheral blood cell autografts contain residual tumour cells due to impurity, not to CD34+ myeloma cells. Br J Haematol 93 (1996) 613-622
10. Schiller G., Vescio R., Freytes C., et al. Autologous CD34-selected blood progenitor cell transplants for patients with advanced multiple myeloma. Bone Marrow Transplant 21 (1998) 141-145
11. Rasmussen T., Jensen L., Honore L., Andersen H., and Johnsen H.E. Circulating clonal cells in multiple myeloma do not express CD34 mRNA, as measured by single-cell and real-time RT-PCR assays. Br J Haematol 107 (1999) 818-824
12. Rasmussen T., Kastrup J., Knudsen L.M., and Johnsen H.E. High numbers of clonal CD19+ cells in the peripheral blood of a patient with multiple myeloma. Br J Haematol 105 (1999) 265-267
13. Rasmussen T., Bjorkstrand B., Andersen H., Gaarsdal E., and Johnsen H.E. Efficacy and safety of CD34-selected and CD19-depleted autografting in multiple myeloma patients: a pilot study. Exp Hematol 30 (2002) 82-88
14. Stewart A.K., Vescio R., Schiller G., et al. Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trial. J Clin Oncol 19 (2001) 3771-3779
15. Vescio R., Schiller G., Stewart A.K., et al. Multicenter phase III trial to evaluate CD34(+) selected versus unselected autologous peripheral blood progenitor cell transplantation in multiple myeloma. Blood 93 (1999) 1858-1868
16. Mahe B., Milpied N., Hermouet S., et al. G-CSF alone mobilizes sufficient peripheral blood CD34+ cells for positive selection in newly diagnosed patients with myeloma. Br J Haematol 92 (1996) 263-268
17. Liu J., Hamrouni A., Wolowiec D., et al. Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. Blood 110 (2007) 296-304
18. Knudsen L.M., Rasmussen T., Nikolaisen K., and Johnsen H.E. Mobilisation of tumour cells along with CD34+ cells to peripheral blood in multiple myeloma. Eur J Haematol 67 (2001) 289-295
19. Szczepek A.J., Bergsagel P.L., Axelsson L., Brown C.B., Belch A.R., and Pilarski L.M. CD34+ cells in the blood of patients with multiple myeloma express CD19 and IgH mRNA and have patient-specific IgH VDJ gene rearrangements. Blood 89 (1997) 1824-1833
20. Matsui W., Huff C.A., Wang Q., et al. Characterization of clonogenic multiple myeloma cells. Blood 103 (2004) 2332-2336
21. Yaccoby S. The phenotypic plasticity of myeloma plasma cells as expressed by dedifferentiation into an immature, resilient, and apoptosis-resistant phenotype. Clin Cancer Res 11 (2005) 7599-7606
22. Dalton W., and Anderson K.C. Synopsis of a roundtable on validating novel therapeutics for multiple myeloma. Clin Cancer Res 12 (2006) 6603-6610
23. Dao M.A., Arevalo J., and Nolta J.A. Reversibility of CD34 expression on human hematopoietic stem cells that retain the capacity for secondary reconstitution. Blood 101 (2003) 112-118
24. Dooley D.C., Oppenlander B.K., and Xiao M. Analysis of primitive CD34- and CD34+ hematopoietic cells from adults: gain and loss of CD34 antigen by undifferentiated cells are closely linked to proliferative status in culture. Stem Cells 22 (2004) 556-569
25. Zanjani E.D., Almeida-Porada G., Livingston A.G., Zeng H., and Ogawa M. Reversible expression of CD34 by adult human bone marrow long-term engrafting hematopoietic stem cells. Exp Hematol 31 (2003) 406-412